Inactivation virale par procédé solvant-détergent de minipools de plasma, de cryoprécipité et de surnageant de cryoprécipité dans des dispositifs à usage unique

Translated title of the contribution: Solvent-detergent viral inactivation of minipools of plasma for transfusion, cryoprecipitate and cryo-poor plasma in single-use bag systems

T. Burnouf, H. A. Goubran, M. Radosevich, M. El-Ekiaby

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Non-virally inactivated plasma, cryoprecipitate and cryoprecipitate-poor plasma, prepared by blood establishments, are still used in many countries in the world, in both the developing world and industrialized countries, for the treatment of various hematological disorders. In the absence of viral inactivation treatment, these fractions may be involved, in spite of increasingly sensitive viral detection methods, into the transmission of plasma-borne viruses, most critically HIV and Hepatitis B (HBV) or C (HCV). We have adapted the well-established industrial solvent-detergent (SD) viral inactivation treatment to allow its application in a small scale using a single-use plastic bag system. The procedure can be used by blood establishments, without the need to build an industrial-scale manufacturing facility. Results show a good recovery of the functional activity of plasma proteins, including coagulation factors (such as factor VIII and coagulable fibrinogen) and/or protease inhibitors (such as alpha 2-antiplasmin). Viral validation studies revealed reduction factors greater than 4.17, greater than 4.73 and greater than 4.72 for HIV, BVDV and PRV, respectively, within a few minutes of treatment. A single-use SD treatment and SD-elimination system is currently under development to allow standardized use of the procedure by blood establishments or national or regional service centers.

Original languageFrench
Pages (from-to)129-134
Number of pages6
JournalTransfusion Clinique et Biologique
Volume15
Issue number3
DOIs
Publication statusPublished - Jun 2008
Externally publishedYes

Fingerprint

Virus Inactivation
Detergents
Blood
Plasmas
alpha-2-Antiplasmin
HIV
Blood Coagulation Factors
Validation Studies
Factor VIII
Hepatitis C
Protease Inhibitors
Hepatitis B
Viruses
Developed Countries
Fibrinogen
Developing Countries
Plastics
Blood Proteins
Recovery

Keywords

  • Cryo-poor plasma
  • Cryoprecipitate
  • Disposables
  • Minipool
  • Plasma
  • Solvent-detergent
  • Virus

ASJC Scopus subject areas

  • Hematology

Cite this

Inactivation virale par procédé solvant-détergent de minipools de plasma, de cryoprécipité et de surnageant de cryoprécipité dans des dispositifs à usage unique. / Burnouf, T.; Goubran, H. A.; Radosevich, M.; El-Ekiaby, M.

In: Transfusion Clinique et Biologique, Vol. 15, No. 3, 06.2008, p. 129-134.

Research output: Contribution to journalArticle

@article{092e45bb295a459585241d693c24e36f,
title = "Inactivation virale par proc{\'e}d{\'e} solvant-d{\'e}tergent de minipools de plasma, de cryopr{\'e}cipit{\'e} et de surnageant de cryopr{\'e}cipit{\'e} dans des dispositifs {\`a} usage unique",
abstract = "Non-virally inactivated plasma, cryoprecipitate and cryoprecipitate-poor plasma, prepared by blood establishments, are still used in many countries in the world, in both the developing world and industrialized countries, for the treatment of various hematological disorders. In the absence of viral inactivation treatment, these fractions may be involved, in spite of increasingly sensitive viral detection methods, into the transmission of plasma-borne viruses, most critically HIV and Hepatitis B (HBV) or C (HCV). We have adapted the well-established industrial solvent-detergent (SD) viral inactivation treatment to allow its application in a small scale using a single-use plastic bag system. The procedure can be used by blood establishments, without the need to build an industrial-scale manufacturing facility. Results show a good recovery of the functional activity of plasma proteins, including coagulation factors (such as factor VIII and coagulable fibrinogen) and/or protease inhibitors (such as alpha 2-antiplasmin). Viral validation studies revealed reduction factors greater than 4.17, greater than 4.73 and greater than 4.72 for HIV, BVDV and PRV, respectively, within a few minutes of treatment. A single-use SD treatment and SD-elimination system is currently under development to allow standardized use of the procedure by blood establishments or national or regional service centers.",
keywords = "Cryo-poor plasma, Cryoprecipitate, Disposables, Minipool, Plasma, Solvent-detergent, Virus",
author = "T. Burnouf and Goubran, {H. A.} and M. Radosevich and M. El-Ekiaby",
year = "2008",
month = "6",
doi = "10.1016/j.tracli.2008.04.007",
language = "法语",
volume = "15",
pages = "129--134",
journal = "Transfusion Clinique et Biologique",
issn = "1246-7820",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Inactivation virale par procédé solvant-détergent de minipools de plasma, de cryoprécipité et de surnageant de cryoprécipité dans des dispositifs à usage unique

AU - Burnouf, T.

AU - Goubran, H. A.

AU - Radosevich, M.

AU - El-Ekiaby, M.

PY - 2008/6

Y1 - 2008/6

N2 - Non-virally inactivated plasma, cryoprecipitate and cryoprecipitate-poor plasma, prepared by blood establishments, are still used in many countries in the world, in both the developing world and industrialized countries, for the treatment of various hematological disorders. In the absence of viral inactivation treatment, these fractions may be involved, in spite of increasingly sensitive viral detection methods, into the transmission of plasma-borne viruses, most critically HIV and Hepatitis B (HBV) or C (HCV). We have adapted the well-established industrial solvent-detergent (SD) viral inactivation treatment to allow its application in a small scale using a single-use plastic bag system. The procedure can be used by blood establishments, without the need to build an industrial-scale manufacturing facility. Results show a good recovery of the functional activity of plasma proteins, including coagulation factors (such as factor VIII and coagulable fibrinogen) and/or protease inhibitors (such as alpha 2-antiplasmin). Viral validation studies revealed reduction factors greater than 4.17, greater than 4.73 and greater than 4.72 for HIV, BVDV and PRV, respectively, within a few minutes of treatment. A single-use SD treatment and SD-elimination system is currently under development to allow standardized use of the procedure by blood establishments or national or regional service centers.

AB - Non-virally inactivated plasma, cryoprecipitate and cryoprecipitate-poor plasma, prepared by blood establishments, are still used in many countries in the world, in both the developing world and industrialized countries, for the treatment of various hematological disorders. In the absence of viral inactivation treatment, these fractions may be involved, in spite of increasingly sensitive viral detection methods, into the transmission of plasma-borne viruses, most critically HIV and Hepatitis B (HBV) or C (HCV). We have adapted the well-established industrial solvent-detergent (SD) viral inactivation treatment to allow its application in a small scale using a single-use plastic bag system. The procedure can be used by blood establishments, without the need to build an industrial-scale manufacturing facility. Results show a good recovery of the functional activity of plasma proteins, including coagulation factors (such as factor VIII and coagulable fibrinogen) and/or protease inhibitors (such as alpha 2-antiplasmin). Viral validation studies revealed reduction factors greater than 4.17, greater than 4.73 and greater than 4.72 for HIV, BVDV and PRV, respectively, within a few minutes of treatment. A single-use SD treatment and SD-elimination system is currently under development to allow standardized use of the procedure by blood establishments or national or regional service centers.

KW - Cryo-poor plasma

KW - Cryoprecipitate

KW - Disposables

KW - Minipool

KW - Plasma

KW - Solvent-detergent

KW - Virus

UR - http://www.scopus.com/inward/record.url?scp=47749141093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47749141093&partnerID=8YFLogxK

U2 - 10.1016/j.tracli.2008.04.007

DO - 10.1016/j.tracli.2008.04.007

M3 - 文章

VL - 15

SP - 129

EP - 134

JO - Transfusion Clinique et Biologique

JF - Transfusion Clinique et Biologique

SN - 1246-7820

IS - 3

ER -